For Stephen L. Hauser, MD, an investigator in the ASCLEPIOS trials, these results represent a decades-long journey to better understand MS and what he calls a “magnificent success story” in the overall treatment of the disease.
“Ofatumumab shuts down new focal inflammatory activity nearly completely. It reduces relapse-independent disability progression, and at least in the clinical trial data to date, it has a very favorable safety profile. I believe that clinicians should consider the use of highly effective therapy with an agent like ofatumumab very early in the disease course,”
Good news? Sounds like it to me. What do you think?
This topic was modified 3 months, 2 weeks ago by John Connor.
Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.